ABSTRACT NUMBER - L05

Treating Macular Degeneration: Looking to the Future


Joan W Miller MD

Meeting:  2013 RANZCO


SESSION INFORMATION

Date: 05 Nov 2013

Session Title: RETINA UPDATE LECTURE

Session Time: 10:20 am - 10:50 am

There have been tremendous advancements in the treatment of age-related macular degeneration(AMD) in the last decade. In 2003, therapy for neovascular AMD had advanced from laser pho-tocoagulation to verteporfin photodynamic therapy, and the field was verging on the era of treat-ments targeting vascular endothelial growth factor (VEGF). Now, in 2013, retina specialists arecomfortable with the results obtained with anti-VEGF therapy in neovascular AMD, and ongoinginvestigations seek to provide long-term delivery and broaden strategies for angiogenesis inhibi-tion. However, we all recognize that it would be preferable to prevent the disease, or be able tointervene in the early stages of AMD in order to forestall progression and preserve normal visualfunction, and this strategy requires a better understanding of AMD pathogenesis. In 2013, we areagain verging on new therapies for AMD. Genetic and functional studies have increased ourunderstanding of disease pathogenesis, allowing us to pursue more targeted therapeutic strategies.In this lecture, I will provide an overview of the clinical observations, molecular evidence andgenetic discoveries that have identified pathways for therapeutic targeting, including lipid metabo-lism and deposition, angiogenesis, and immune or inflammatory functions. This approach leads toan integrated model of AMD, which in turn provides a rationale framework for emergingapproaches in AMD therapy.

MOST VIEWED ABSTRACTS


ARCHIVES